Testing teclistamab with iberdomide for relapsed or refractory multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new combination of two drugs (teclistamab and iberdomide) for people with multiple myeloma that has come back or stopped responding to standard treatments. The goal is to see how well this combination works and whether it can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have multiple myeloma that has returned or not responded to at least 4 previous treatments, including a proteasome inhibitor (like bortezomib), an immunomodulatory drug (like lenalidomide), and an anti-CD38 antibody (like daratumumab).
- If you had a stem cell transplant using your own cells, it must have been more than 100 days ago.
- You cannot have had certain types of prior treatments that target BCMA (like bispecific antibodies, antibody-drug conjugates, or CAR-T therapy), nor prior treatment with drugs like iberdomide or mezigdomide.
- You need to have measurable signs of the disease, such as a certain level of M-protein in blood or urine, or free light chains in blood.
- You must be 18 or older, have an ECOG performance status of 2 or better (meaning you are able to do most daily activities), and have adequate blood counts and organ function (kidney and liver).
- You cannot be pregnant or breastfeeding, and must agree to use effective birth control during the study and for a period after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three drugs: talquetamab (a bispecific antibody), iberdomide (a pill), and dexamethasone (a steroid) for people with multiple myeloma that has returned or become resistant after other treatments. The goal is to see if this triplet is safe and effective at shrinking the cancer.
This trial tests a combination of two antibody drugs (elotuzumab and daratumumab) plus an oral pill (iberdomide) and a steroid (dexamethasone) for people whose multiple myeloma has come back after treatment. The goal is to see if this new mix works better than what's already available.
This study tests a new combination of two drugs, teclistamab and pomalidomide, against the usual treatment of three drugs for multiple myeloma that has come back shortly after a standard treatment. The goal is to see if the new combination works better or is safer.
This trial tests whether a new combination of drugs (daratumumab and teclistamab) works better than the usual treatments for multiple myeloma that has come back or stopped responding, especially in people with a high-risk form of the disease. Participants will be randomly assigned to get either the new combo or one of the standard combos.
This Phase 2 trial tests iberdomide plus daratumumab, carfilzomib, and dexamethasone in people whose multiple myeloma has come back or not responded. The goal is to increase how often patients reach “MRD-negative” status, meaning very small amounts of cancer cells are not detectable, which may help improve outcomes.
This study tests a new experimental drug (JNJ-79635322) compared to another targeted immunotherapy (Teclistamab) for people with multiple myeloma that has returned or not responded after several prior treatments.
Hear when a new Recurrent Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.